ReviewFrontiers in ophthalmology2025
The evolving role of ciclosporin in the management of vernal keratoconjunctivitis.
Review in Frontiers in ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the spectrum of allergic eye disease, vernal keratoconjunctivitis (VKC) is classed as one of the most severe disease entities and can have profound effects on visual development as well as on the emotional and psychological well-being of afflicted children. The traditional mainstay of treatment for the condition, to control the ocular inflammation, has been steroids but the use of these drugs has not been without side effects. Ciclosporin offers an alternative to steroids, providing symptom relief and control of the ocular inflammation, whilst averting the problems associated with raised intraocular pressure, cataract formation and reactivation of herpes simplex keratitis, all recognised side effects of topical steroids. However, the journey to the development of a formulation of an unpreserved ciclosporin for use in human eyes has been a protracted one; the aim of this article is to outline this journey and the role of ciclosporin in the modern management of this debilitating disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.